In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Galmed Pharmaceuticals (GLMD – Research Report), with a price target of $3.00. The company's shares closed last Tuesday at $0.91, close to its 52-week low of $0.78. According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -38.8% and a 9.8% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Neurosense Therapeutics Ltd., Processa Pharmaceuticals, and Quoin Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Galmed Pharmaceuticals with a $4.00 average price target, implying a 270.
https://www.tipranks.com/news/blurbs/maxim-group-thinks-galmed-pharmaceuticals-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Galmed Pharmaceuticals (NASDAQ:GLMD)
Gráfico Histórico do Ativo
De Jul 2022 até Ago 2022 Click aqui para mais gráficos Galmed Pharmaceuticals.
Galmed Pharmaceuticals (NASDAQ:GLMD)
Gráfico Histórico do Ativo
De Ago 2021 até Ago 2022 Click aqui para mais gráficos Galmed Pharmaceuticals.